

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

### REMARKS

#### The Claim Amendments

Applicants have amended claims 1, 22, 45, 48 and 50 to correspond the claims to elected Group V. Support for this amendment may be found in the originally filed claims and throughout the specification. None of the amendments contain new matter. Their entry is requested.

#### The Restriction

The Examiner has required a restriction in the above-identified application under 35 U.S.C. § 121 to one of the following five groups:

- I. Claims 1-33 and 46-53, drawn to compounds of formula I wherein  $Z^1$  and  $Z^2$  are nitrogen and  $Z^3$  is  $CR^z$ , corresponding compositions and methods of use;
- II. Claims 1-33 and 46-53, drawn to compounds of formula I wherein  $Z^1$  and  $Z^3$  are nitrogen and  $Z^2$  is  $CR^z$ , corresponding compositions and methods of use;
- III. Claims 1-33 and 46-53, drawn to compounds of formula I wherein  $Z^2$  is nitrogen and  $Z^1$  and  $Z^3$  are  $CR^z$ , corresponding compositions and methods of use;
- IV. Claims 1-33 and 46-53, drawn to compounds of formula I wherein  $Z^1$  or  $Z^2$  is nitrogen and the other is  $CR^z$  and  $Z^3$  are  $CR^z$ , corresponding compositions and methods of use; and
- V. Claims 1-53, drawn to compounds of formula I wherein  $Z^1$ ,  $Z^2$  and  $Z^3$  are  $CR^z$ , corresponding compositions and methods of use;

Applicants elect Group V **without** traverse.

#### The Election of Species

The Examiner states that the application contains claims directed to the following patentably distinct species of the claimed invention: isomeric triazine, isomeric pyrimidine and pyridazine and pyridine species. The Examiner has required an election of species under 35 U.S.C. § 121.

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

Applicants elect species I-290 **without** traverse. Claims 1-53 read on the elected species.

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,



---

Karen E. Brown  
Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483